Celldex Nabs $10M Milestone

Needham, MA-based Celldex Therapeutics (NASDAQ: CLDX) said it has received a $10 million milestone payment triggered by the U.S. launch of the oral rotavirus vaccine Rotarix, which is marketed by GlaxoSmithKline (NYSE: GSK). Celldex was formed through the recent merger of Avant Immunotherapeutics of Needham and Phillipsburg, NJ-based Celldex Therapeutics.

Trending on Xconomy